{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:17:42Z","timestamp":1774124262610,"version":"3.50.1"},"reference-count":68,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"vor","delay-in-days":6213,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1995,7]]},"abstract":"<jats:p>1. The role of vasoactive peptide systems in the pulmonary vasculature has been studied much less extensively than systemic vascular and endocrine effects. The current understanding of the role of the renin\u2010 angiotensin (RAS) and natriuretic peptide systems (NPS) in the pulmonary circulation is therefore reviewed. 2. Plasma concentrations of angiotensin II, the main vasoactive component of the RAS, are elevated in pulmonary hypertension and may interact with hypoxaemia to cause further pulmonary vasoconstriction. Pharmacological manipulation of angiotensin II can attenuate hypoxic pulmonary vasoconstriction but larger studies are needed to establish the efficacy of this therapeutic strategy in established pulmonary hypertension. 3. Although all the known natriuretic peptides, ANP, BNP and CNP are elevated in cor pulmonale, only ANP and BNP appear to have pulmonary vasorelaxant activity in humans. ANP and BNP can also attenuate hypoxic pulmonary vasoconstriction, suggesting a possible counter\u2010regulatory role for these peptides. Inhibition of ANP\/BNP metabolism by neutral endopeptidase has been shown to attenuate development of hypoxic pulmonary hypertension but this property has not been tested in humans. 4. It is also well established that there are potentially important endocrine and systemic circulatory interactions between the RAS and NPS. This also occurs in the pulmonary circulation and in humans, where at least BNP acts to attenuate angiotensin II induced pulmonary vasoconstriction. This interaction may be particularly relevant as a mechanism to counter\u2010regulate overactivity of the RAS.(ABSTRACT TRUNCATED AT 250 WORDS)<\/jats:p>","DOI":"10.1111\/j.1365-2125.1995.tb04528.x","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T05:53:51Z","timestamp":1341467631000},"page":"11-18","source":"Crossref","is-referenced-by-count":27,"title":["The role of the renin\u2010angiotensin and natriuretic peptide systems in the pulmonary vasculature."],"prefix":"10.1111","volume":"40","author":[{"given":"RI","family":"Cargill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BJ","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000391-00005"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.66.4.264"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90530-8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04117.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_1_7_2","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema","author":"Medical Research Council Working Party","year":"1981","journal-title":"Lancet"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91452-1"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archinte.1982.00340200086019","article-title":"Abnormalities of sodium and H20 handling in chronic obstructive lung disease","volume":"142","author":"Faber MO","year":"1982","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.48.6.541"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/archinte.1971.00310160232020","article-title":"Renal function in respiratory failure","volume":"127","author":"Kilburn KH","year":"1971","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.86.1.12"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.97.4.840"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj1460497"},{"key":"e_1_2_1_15_2","first-page":"49","article-title":"The effects of synthetic hypertension on the systemic and pulmonary circulations in man","volume":"20","author":"Segel N.","year":"1960","journal-title":"Clin Sci"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.5.1360"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1152\/jappl.1992.73.5.2054","article-title":"Inhibitory effects of DuP 753 and EXP 3174 on responses to angiotensin II in pulmonary vascular bed of the cat","volume":"73","author":"McMahon TJ","year":"1992","journal-title":"J Appl Physiol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.35.2.256"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1984.56.2.375"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1152\/jappl.1976.41.1.84","article-title":"Effect of angiotensin on hypoxic pulmonary vasoconstriction in isolateddog lung","volume":"41","author":"Alexander JM","year":"1976","journal-title":"J Appi Physiol"},{"key":"e_1_2_1_21_2","article-title":"Combined effects of hypoxaemia and angiotensin II in the human pulmonary vascular bed","author":"Cargill RI","year":"1995","journal-title":"Pulm Pharmacol"},{"key":"e_1_2_1_22_2","first-page":"57","article-title":"Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I\u2010converting enzyme in the rat","volume":"33","author":"Zakheim RM","year":"1975","journal-title":"Lab Invest"},{"issue":"18","key":"e_1_2_1_23_2","first-page":"104S","article-title":"Lisinopril attenuates the hypoxic pulmonary vasoconstrictor response. Evidence for a facilitatory role of angiotensin II","volume":"7","author":"Cargill RI","year":"1994","journal-title":"Eur Resp J"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/11.6.541"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"75S","DOI":"10.1042\/cs059075s","article-title":"Angiotensin II and not sodium status is the major determinant of the agonistic\/antagonistic balance of saralasin's actions","volume":"59","author":"Fagard R.","year":"1980","journal-title":"Clin Sci"},{"key":"e_1_2_1_26_2","first-page":"217","article-title":"Persistent haemodynamic and clinical improvement after captopril in patients with pulmonary hypertension","volume":"11","author":"Stumpe KO","year":"1986","journal-title":"Herz"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.67.1.155"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/oxfordjournals.eurheartj.a060255","article-title":"Drug testing in patients with pulmonary hypertension of unknown cause","volume":"13","author":"Kreiner G.","year":"1992","journal-title":"Eur Heart J"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000194843"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.50.1055"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000194887"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.90.4.562"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.64.749.193"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(06)80143-5"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6477.1251"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000195888"},{"key":"e_1_2_1_37_2","first-page":"377","article-title":"Management of pulmonary hypertension","volume":"17","author":"Peacock AJ.","year":"1991","journal-title":"Hospital Update"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0830519"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6707.1081"},{"key":"e_1_2_1_40_2","first-page":"70","article-title":"Changes of atrial natriuretic peptide plasma levels in patients with pulmonary embolism and obstructive lung disease","volume":"44","author":"Noll B.","year":"1990","journal-title":"Pneumologie"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1183\/09031936.93.03080910","article-title":"Atrial natriuretic peptide pulmonary hypertension","volume":"3","author":"Morice AH","year":"1990","journal-title":"Eur Resp J"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0830529"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.12.1247"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.3.1004"},{"key":"e_1_2_1_45_2","first-page":"H295","article-title":"Acute hypoxaemia stimulates atrial natriuretic factor secretion in vivo","volume":"255","author":"Baertschi A.","year":"1988","journal-title":"Am J Physiol"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0034-5687(89)90019-4"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0760095"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)70269-X"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1210\/endo.130.1.1309330","article-title":"Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide and c\u2010type natriuretic peptide","volume":"130","author":"Suga S.","year":"1992","journal-title":"Endocrinology"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(91)90026-9"},{"issue":"1","key":"e_1_2_1_51_2","first-page":"604","article-title":"Pulmonary vasodilator properties of natriuretic peptides","volume":"86","author":"Lippton H.","year":"1992","journal-title":"Circulation"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb11263.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0830723"},{"key":"e_1_2_1_54_2","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1152\/jappl.1988.65.5.1975","article-title":"Atrial natriuretic factor attenuates the pulmonary pressor response to hypoxia","volume":"65","author":"Adnot S","year":"1988","journal-title":"J Appl Physiol"},{"key":"e_1_2_1_55_2","first-page":"11","article-title":"Atrial natriuretic X 1995 Blackwell Science Ltd","volume":"40","author":"Cody RJ","journal-title":"British Journal of Clinical Pharmacology"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.4.1581"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.2.183"},{"key":"e_1_2_1_58_2","first-page":"108","article-title":"Human c\u2010type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II","volume":"29","author":"Cargill RI","year":"1995","journal-title":"Cardiovascular Res"},{"key":"e_1_2_1_59_2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1152\/jappl.1989.67.4.1606","article-title":"Does atrial natriuretic factor protect against right ventricular overload? 1. Haemodynamic study","volume":"67","author":"Ou LC","year":"1989","journal-title":"J Appl Physiol"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/146.5_Pt_1.1198"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0810379"},{"issue":"32","key":"e_1_2_1_62_2","article-title":"Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans","volume":"88","author":"Cargill RI","year":"1995","journal-title":"Clin Sci"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113985"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.3.233"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90397-8"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/144.6.1342"},{"key":"e_1_2_1_67_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/cs0870109","article-title":"Effects of the neutral endopeptidase inhibitor SCH 42495 on the cardiovascular remodelling secondary to chronic hypoxia in rats","volume":"87","author":"Thompson JS","year":"1994","journal-title":"Clin Sci"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)91196-B"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/0952-0600(90)90006-5"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1995.tb04528.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1995.tb04528.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:04:15Z","timestamp":1698300255000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1995.tb04528.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,7]]}},"alternative-id":["10.1111\/j.1365-2125.1995.tb04528.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1995.tb04528.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,7]]}}}